Literature DB >> 10340504

Frequent colocalization of mu opioid and NMDA-type glutamate receptors at postsynaptic sites in periaqueductal gray neurons.

K G Commons1, E J van Bockstaele, D W Pfaff.   

Abstract

In the ventrolateral periaqueductal gray (PAG), endogenous pathways which dampen pain transmission can be activated by either opioids or excitatory amino acids such as N-methyl D-aspartate (NMDA). The effects of these ligands may converge, because morphine-produced analgesia in the PAG can be blocked by NMDA receptor antagonists. To determine the relationship between the subcellular sites where opioid ligands of the mu opioid receptor (MOR) and NMDA receptor ligands may act, we studied the ultrastructural distribution of immunolabeling for MOR and the R1 subunit of the NMDA receptor (NR1) in the ventrolateral PAG. MOR labeling was most commonly distributed along extrasynaptic regions of the plasma membrane of neuronal dendrites (80% or 245/306). In addition, MOR labeling was found presynaptically in axon terminals (13% or 39/306) which preferentially formed symmetric (inhibitory-type) synapses. NR1 immunoreactivity was also prevalent in dendrites (72% or 242/335), but in contrast to MOR, was usually associated with a subset of postsynaptic densities. Axon terminals (5%, 17/335) and glial processes (18%, 61/335) comprised the remainder of NR1-labeled profiles. There was a striking colocalization of MOR and NR1 labeling within dendrites. The majority of NR1-labeled dendrites contained MOR labeling (72%, 176/242) and likewise, the majority of MOR-labeled dendrites contained NR1 labeling (72%, 176/245). Thus, mu opioid and NMDA receptor ligands may act at several overlapping subcellular sites to modulate behaviors subserved by the ventrolateral PAG, such as antinociception.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340504

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  27 in total

1.  Association of mu-opioid and NMDA receptors in the periaqueductal gray: what does it mean for pain control?

Authors:  Susan L Ingram
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

2.  Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.

Authors:  Emily O Dumas; Gary M Pollack
Journal:  AAPS J       Date:  2008-11-07       Impact factor: 4.009

3.  The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control.

Authors:  María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Ana Vicente-Sánchez; Esther Berrocoso; Javier Garzón
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

4.  Enhanced phosphorylation of NMDA receptor 1 subunits in spinal cord dorsal horn and spinothalamic tract neurons after intradermal injection of capsaicin in rats.

Authors:  X Zou; Q Lin; W D Willis
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

Review 5.  Inflammatory mediators of opioid tolerance: Implications for dependency and addiction.

Authors:  Lori N Eidson; Anne Z Murphy
Journal:  Peptides       Date:  2019-03-16       Impact factor: 3.750

6.  Influence of intramuscular heat stimulation on modulation of nociception: complex role of central opioid receptors in descending facilitation and inhibition.

Authors:  Hao-Jun You; Jing Lei; Gang Ye; Xiao-Li Fan; Qiang Li
Journal:  J Physiol       Date:  2014-07-18       Impact factor: 5.182

Review 7.  Glutamate receptors and nociception: implications for the drug treatment of pain.

Authors:  M E Fundytus
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

8.  Endometriosis Is Associated With a Shift in MU Opioid and NMDA Receptor Expression in the Brain Periaqueductal Gray.

Authors:  Annelyn Torres-Reverón; Karylane Palermo; Anixa Hernández-López; Siomara Hernández; Myrella L Cruz; Kenira J Thompson; Idhaliz Flores; Caroline B Appleyard
Journal:  Reprod Sci       Date:  2016-04-18       Impact factor: 3.060

9.  Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.

Authors:  Nolan R Williams; Boris D Heifets; Christine Blasey; Keith Sudheimer; Jaspreet Pannu; Heather Pankow; Jessica Hawkins; Justin Birnbaum; David M Lyons; Carolyn I Rodriguez; Alan F Schatzberg
Journal:  Am J Psychiatry       Date:  2018-08-29       Impact factor: 18.112

10.  Role of endogenous sleep-wake and analgesic systems in anesthesia.

Authors:  Jun Lu; Laura E Nelson; Nick Franks; Mervyn Maze; Nancy L Chamberlin; Clifford B Saper
Journal:  J Comp Neurol       Date:  2008-06-01       Impact factor: 3.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.